{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"30.9","value":"8.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"To determine the median overall survival for patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma treated with pemetrexed and gemcitabine.","dispersionType":"Full Range","groups":[{"description":"Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle.","id":"OG000","title":"Pemetrexed Plus Gemcitabine"}],"paramType":"MEDIAN","populationDescription":"There were 25 assessable patients as described in the protocol.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Median Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}